non-governmental organisations, or facilities serving solely as referral centres, patients with incomplete laboratory data and patients with NTM infection or a change in diagnosis Meyssonnier et al. () Retrospective N=39 RIF-mono-resistant TB Inclusion Treatment with Treatment with Health outcomes cohort study patients, data about treatment antibiotics other RIF-containing (recovery, lost to France All patients diagnosed with and outcome were available than RIF antibiotic regimen death, relapse) Level: III-2 mono-resistant TB reported to the for 30 patients national network in France between Quality: 18/26 19 males (49%), median age 2005 and 2010 Some risk of bias 43 years (IQR 29–58) Foreign born 18 (46%) IQR = interquartile range; MDR = multidrug-resistant; NTM = non-tuberculous mycobacteria; RIF = rifampicin; TB = tuberculosis; DST = drug susceptibility testing Table 100 Study profiles of SRs assessing the safety and adverse effects of active TB therapies Author Study design Research question Population Intervention Comparator Outcomes Country Quality appraisal Included studies (N) Forget and Systematic review (literature Research question: Active TB patients Isoniazid, rifampicin, Various Discontinuation rate Menzies () search of Medline, relevant pyrazinamide, NS Latent TB patients AE rate articles from authors’ files and ethambutol, streptomycin Canada Included studies: TB patients on multidrug Mortality rate pearled references from cited Multidrug regimens regimens NS Risk factors for articles) development of AEs Quality appraisal: poor High risk of bias Frydenberg & Systematic review (literature Research question: Children (0–18 years of age) Anti-TB agents, isoniazid, NS Adverse reaction Graham () search of PubMed, EMBASE undergoing first-line therapy for rifampicin, pyrazinamide, incidence To review the frequency and and Cochrane Library TB, or therapy for latent TB ethambutol, streptomycin Australia manifestations of toxicities in AE rate Reference, hand-search of children to current first-line Combination therapies reference lists) anti-TB therapy
non-governmental organisations, or facilities serving solely as referral centres, patients with incomplete laboratory data and patients with NTM infection or a change in diagnosis Meyssonnier et al. () France Retrospective cohort study Level: III-2 Quality: 18/26 Some risk of bias N=39 RIF-mono-resistant TB patients, data about treatment and outcome were available for 30 patients 19 males (49%), median age 43 years (IQR 29–58) Foreign born 18 (46%) Inclusion All patients diagnosed with TB reported to the national network in France between 2005 and 2010 Treatment with antibiotics other than RIF Treatment with RIF-containing antibiotic regimen Health outcomes (recovery, lost to death, relapse) IQR = interquartile range; MDR = multidrug-resistant; NTM = non-tuberculous mycobacteria; RIF = rifampicin; TB = tuberculosis; DST = drug susceptibility testing Table 100 Study profiles of SRs assessing the safety and adverse effects of active TB therapies Author Country Study design Quality appraisal Research question Included studies (N) Population Intervention Comparator Outcomes Forget and Menzies () Canada Systematic review (literature search of Medline, relevant articles from authors’ files and pearled references from cited articles) Quality appraisal: poor High risk of bias Research question: NS Included studies: NS Active TB patients Latent TB patients TB patients on multidrug regimens Isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin Multidrug regimens Various Discontinuation rate AE rate Mortality rate Risk factors for development of AEs Frydenberg & Graham () Australia Systematic review (literature search of PubMed, EMBASE and Cochrane Library Reference, hand-search of reference lists) Research question: To review the frequency and manifestations of toxicities in children to current first-line anti-TB therapy Children (0–18 years of age) undergoing first-line therapy for TB, or therapy for latent TB Anti-TB agents, isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin Combination therapies NS Adverse reaction incidence AE rate mono-resistant
1234_FinalAssessmentReport-accessible.docx